The technical and diagnostic performance of fully automated immunoassays for free thyroxine and thyrotropin using streptavidin/biotui technology (Enzymun-Test®) were examined. The between-assay precision for ! free thyroxine was 10.4%, 5.4%, 2.5%, 2.3%, 1.1% and 1.8% at 3. 02, 6.27, 17.2, 21.9, 25.6, 42.7 pmol/I; and for | thyrotropin was 14.2%, 4.7%, 2.9%, 2.8%, 3.2%, 4.5% at 0.12, 0.46, 1.03, 2.05, 4.8, 12.7 mU/1. The functional 1 detection limit of the assay was 0.09 mU/1. Results for the free thyroxine method correlated well with the IMx (r =0.91) and the equilibrium dialysis (r = 0.95) assay. Results for the thyrotropin method correlated well with the Tandem®-TSH (r = 0.99) and the IMx (r = 0.99) assays. The euthyroid reference r nge was 11-23 pmol/1 and 0.5-3.9 mU/1 for free thyroxine and thyrotropin respectively. The free thyroxine assay was not influenced by changes in albumin or thyroxine binding globulin concentration but showed increases at oleic acid concentrations | > 4 mmol/1. Spuriously elevated free thyroxine concentration were found in 4 patients, due to assay interference i by antibodies in the serum. In a follow up study of 46 patients with non-thyroidal illness, serial measurements * showed fluctuating free thyroxine and thyrotropin concentrations with abnormal results occurring in 34%. In a hospital setting, a wider r nge pf free thyroxine (10-28 pmol/1) and thyrotropin (0.22-5.9 mU/1) concentration ι may be observed in patients who are clinically euthyroid. Abnormal thyroid function tests were however transient , and follow up resolved most diagnostic problems.
Introduction
Recently, fully automated tests using streptavidin/biotin _.,.._,, , , -Λ. ι technology for free thyroxine and thyrotropin (EnzyThe chmcal laborat ry must, tpday, select its free thy-_ TJL . ^ , , ,, ; . Λ . , " . A ,. , ~. mun-Test^) were mtroduced on the automated immunoroxine and thyrotropin assays from a multitude of iso-. Τ?ΟΟΛΛ /r> u · \Λ u · \* , . . , Λ ,ι j a ssay analyser, ES300 (Boehrmger Mannheim, Manntopic and non-isotopic and manual or fully automated , .
_ ^ r * · * * . . . ' ,, ,f rx _, ; f , ^ heim, Germany). In theory, conjugate assays for free methods available (1^5). The measurement of thyrotro-.
.
. t' ,-· i ; i thyroxine such s the Enzymun^Test® are attractive bepm and free thyroxine. m serum, iri the clinical labora^ , 1 than manual immunoextraction methods. quantitative or qualitative changes in thynoxine binding to serum proteins, and in non4hyroidal illness, espe-The aim of this study was to evaluate the analytical and cially in an intensive care unit setting (6) . Thyrotropin clinical performance of the Enzymun-Test® FT 4 and Enassays vary in their quoted analytical sensitivity, and in zymun-Test® TSH in a ro tine laborat ry setting. the use of different calibrators constructed froiii different non human-based 'Serum matrices (7) . Also at present the majority of commercially available second genera-Materials and Methods tion thyrotropin assays cannot reliably distinguish be-samples tween mildly subnormal thyrotropin v lues seen in hos--ur -i^u -jA.fi, . ,. -. " , /. , . t -T° determme the reference mtervals for thyrotropin and free thypitahsed patients and the low v lues found m thyrotoxic roxinej the serum con centrations were raeasured in IOO healthy patients (8) .
euthyroid individuals (age 45 ± II years % 58 male, 42 female).
Similarly free thyroxine and thyrotropin in the first and third trimester of pregnancy, oestrogen containing oral contraceptive and Hormone replacement therapy wcre determined in apparently healthy cuthyroid subjects.
For method comparison studies, patient sera sent for routine thyroid function tests were used, and included hypo, hyper and euthyroid patients s well s those on thyroxine and the antiarrhythmic drug amiodarone.
The serum free thyroxine and thyrotropin were followed in two groups of patients with non-thyroidal illness. Group (1), 40 patients (age 74 ± 9 years, 30 male, 10 female) admitted to a general medical ward, with a variety of illness ranging from hairy cell leukaemia, cholecystitis, carcinoma of prostate, vertebral fractures, congestive cardiac failure, were followed over a period of l to 3 months. Following a retrospective study of the patients' medical records 5 patients with previous history of thyroid disease, 3 patients on steroid therapy and 4 patients on amiodarone were exĉ luded from the study.
Group (2), 21 patients (age 74 ± 5 years, 20 male, l female) admitted consecutively to an intensive care unit were followed over a period of l to 5 weeks. The clinical conditions of the patients varied from bypass graft surgery, severe dehydration, partial gastrectomy, thrombectomy and aneurysm repair. Following patient review, 2 patients with prior record of thyroid disease and l patient on amiodarone were excluded from the study.
Method

Thyrotropin
The Enzymun-Test® thyrotropin assay is a two site immunoenzymometric assay involving a biotin labelled antibody and a second monoclonal antibody directed against a different antigenic site, labelled with horseradish peroxidase. Separation was by means of streptavidin coated tubes. The assay was performed according to manufacturer's specification, on the ES300. Seventy μΐ of serum were incubated for 60 minutes at 25 °C, with 700 μΐ of thyrotropin biotinylated antibodies (1.5 mg/1) and antibody conjugate in 80 mmol/1 phosphate buffer pH 7.4. The streptavidin coated tubes were aspirated and washed and the Substrate diammonium 2,2-azino-bis(3-ethylbenzothiazine-6-sulphonate) added. The colour intensity developed in thirty minutes was read at 422 nm.
The Standard concentrations, made up in 'protein matrix', approximated to 0.03, 0.3, 1.02, 9.55, 40.2 mU/l.
Free thyroxine
The Enzymun-Test® FT 4 assay was carried out according to kit inserts, on the ES300. Twenty μΐ of sample or serum was incubated for 30 minutes at 25 °C, with 500 μΐ of biotinylated polyclonal sheep anti-T 4 antibodies (antibody content ^ 100 μ^/l) in 50 mmol/1 barbiturate buffer pH 8.2. Thyroxine peroxidase conjugate (500 μΐ) was then added. After a further incubation for 30 minutes the streptavidin tubes with the reaction mixture were aspirated, washed and the Substrate added. All patient sera were measured in singleton, for both assays.
Sensitivity
Analytical sensitivity, i. e. the minimum concentration at which re·-sults from a serum specimen can be considered statistically different from a zero calibrator + 2.7 SD (99% confidence limit), the latter assayed 10 times, in singleton.
Precision studies
The between assay precision was calculated from the means of 10 singleton measurements of serum specimen aliquoted and stored at -20 °C, and frorn three quality control sera with Iow, medium and high values. The assays were carried out over a period of days (thyrotropin) or weeks (free thyroxine).
The within assay precision was ca'lculated from 10 singleton serum specimens.
Linearity ' r Linearity for thyrotropin was evaluated by two difFerent parallelism studies. Serial dilutions were made of a sample with a high level of thyrotropin with serum containing undetectable levels of thyrotropin, or the thyrotropin diluent provided with the kit. A second sera with a value within the reference r nge was diluted with thyrotropin diluent to test linearity over the lower r nge of the assay.
Method comparison
The accuracy of the free thyroxine method was investigated by comparison with an equilibrium dialysis method (RIA analysis of the dialysate of the undiluted serum, Nichols Institute, San Juan Capistrano, Ca) and by the automated Abbott IMx System (Abbott Park, II., thyroxine specific antibody on microparticles with microparticle enzyme immunoassay technology). The thyrotropin method was compared to the Abbott IMx System (Immunoenzymometric assay with micrpparticle technology, manufacturer's detection limit 0.03 mU/l, referenee r nge 0.32-5.0 mU/l) and the Tarn dem®-TSH (Hybritech, San Diego, Ca) high sensitivity assay (Automated immunoenzymometric assay using coated beads, manufacturer's detection limit 0.1 rnU/I, reference r nge 0.5-6.7 mU/l).
Other assays
Serum thyroxine binding globulin and free triiodothyronme were measured by the Enzymun-Test® assays on the ES300. Prealbumin and human serum albumin were measured by rate nepheiometry on the Beckman Array (Beckman Instruments, Ca.).
Assay interference a. Non-esterifled fatty acids -oleic acid in concentrations from 1 -10 mmol/1 was added to * normal' serum from an apparently healthy indiividual and to patient sera with Iow and normal albumin levels (usirig the method of Mendel et al. (9)), i. e. an aliquot of a solution in isopropanol was evaporated under helium and the residue taken up at 37 °C in serum solution.
b. Albumin -various concentrations of human serum alburnin, fatty acid free (Sigma Chemical Company, St Louis) were added to patient sera with Iow albumin concentration. Negligible levels of free thyroxine were detected in Solutions of human serum lbumi (40 g/l, 20 g/l) when measured by equilibrium dialysis and Enzymun-Test® FT 4 , suggesting that the albumin solution was essentially stripped of thyroxine. Patient sarnples were spiked such that minimal change in volume occurred (i. e. 180 μΐ of concentrated albumin solution to 2 ml) and the albumin level in the patient sera rneasured by nepbel ometry. These samples were then assayed for free thyroxine by the Enzymun-Test® or equilibrium dialysis assay.
c. To determine the nature of proteins causing assay interference -Agarose linked goat anti-human polyvalent immunoglobulins or agarose linked goat anti-human IgG (Sigma Chemical Company), was mixed and centrifuged to remove excess liquid. Two hundred μΐ of serum were incubated with 200 ^g of the solid phase antibody. Free thyroxine assays were carried out on the preincubated serurn.
S tat i s ti es
The curvefit method for the Enzymun-Test® FT 4 
Results
Sensitivity
The analytical sensitivity was 0.08 mU/1 for thyrotropin and 1.2 pmol/1 for free thyroxine. For thyrotropin the functional sensitivity (between-assay CV 10%) approximated to 0.19 mU/1, or (between-assay CV 20%) 0.09 mU/1. The analytical and functional sensitivity of the thyrotropin assay was similar to second generation thyrotropin assays previously studied (10). Within-and between-assay precision are shown in figure l la,b. The precision profile for thyrotropin showed the inverse relationship with low thyrotropin previously rejported for other assays (10) . The between-assay j precision values for both assays, over the euthyroid i ränge, feil within the calculated analytical goals based on intra-individual components of biological Variation (11) . Table l shows the inter-assay precision (CV) for the methods used for comparison. 
Comparison of methods
L Analytical performance
Diagnostic performance
Serum free thyroxine äs measured by the EnzymunTest® and equilibrium dialysis methods concurred in the clässification of 48 patients with free thyroxine values in the euthyroid ränge, 11 patients with free thyroxine in the hyperthyroid ränge and 2 patients with free thyroxine in the hypothyroid ränge. Free thyroxine by the ES300 and free thyroxine (IMx) agreed in the assessment 58 patients with free thyroxine in the euthyroid ränge, 27 patients with elevated free thyroxine concentration, and 10 patients with free thyroxine values below As the percentage of rnisclassifications were small (< 4.0%), the diagnostic performance of EnzymunTest® methods were considered to be equivalent to the comparison techniques; the characteristics of the latter have been described in previous studies (12) (13) (14) (15) .
Reference rariges v'
The noii-parämetric reference intervals (0.025 and 0.975 fractiles) were 11-23 pmol/l for FT 4 and 0.5-3.9 mU/l for thyrotropin (tab. 2). The free thyroxine mean valüe in the first trirnester of pregnancy, 14.8 pmol/l, was found to be significantly higher (p < 0.01) than the 
Assay interference a. Oleic acid
Addition of oleic acid at values greater than 4 mmol/1 i increased the estimates of free thyroxine by both equi-1 librium dialysis and the Enzymun-Test® method in a serum sample from a 'normal' individual with an albumin value of 41 g/l and prealbumin of 250 mg/1. The increase in free thyroxine suggests that thyroxine is displaced from albumin and at higher concentrations from albumin and thyroxine binding globulin by non-esterified fatty acids (33) . Patient sera with low values of albumin responded more sensitively than patient sera with albumin within the reference ränge ( fig. 4) . Endogenous free Free thyroxine by 'Enzymun^Test® in patient sera with albumin 41 g/l, prealbumin 288 mg/1, thyroxine binding globulin 11.9 mg/1.
• Free thyroxine by Enzymun-Test®, in patient sera with albumin 21 g/l, prealbumin 80 mg/l, thyroxine binding globulin 15.6 mg/1. fatty acids were not measured in patient sera but were assumed to be negligible in normal sera. The negligible effect of added albumin suggests that the horseradish peroxidase labelled thyroxine does not significantly bind to albumin. The slight decrease in free thyroxine values by equilibrium dialysis is explained by the long dialysis time (ovemight) resulting in increased binding of thyroxine to serum albumin. As suggested from the regression line the results from the equilibrium dialysis method were generally higher than the Enzymuri-Test® FT 4 . These variations are reflected in the different reference ranges for both assays (Table 3) .
c. Antibody
Four subjects, patients A-D, whose serum free thyroxine values by equilibrium dialysis and IMx were within the reference ränge, gave values above the reference ränge by the Enzymun-Test® FT 4 method (tab. 3). Thyrotropin, free triiodothyronine, thyroxine binding globulin, and prealbumin values were within the reference ränge. Preincubation of the patients' sera with agarose linked goat anti-human immunoglobulin, or agarose liiiked goat anti-human IgG decreased free thyroxine values by 52-71% compared to 7-20% in controls, suggesting that the cause of the spuriously elevated free thyroxine levels, were antibodies (type IgG) present in the sera. Clinical evaluation Group 1: Of the selected patients, 3 patients died during the study Of these, a single patient with chronic renal failure had an abnormal thyrotropin concentration (5.6 mU/1). As in these patients, the focus of treatment was towards the underlying non-thyroidal illness, the abnormalities associated with thyroid function tests caused minimal interpretative problems.
In 8 of the remaining 25 patients, thyroid function tests showed transient abnormalities (tab. 4). One patient had consistently abnormal thyroid function tests over a follow up period of one month (free thyroxine 28.2 pmol/1, thyrotropin 4.9 mU/1). In this patient thyroid function tests became abnormal during repeated admissions for pulmonary oedema and furosemide therapy. As previously, her results were within the reference ränge (free thyroxine 15.1 pmol/1, thyrotropin 2.8 mU/1), her abnormal results were attributed to drug therapy. Overall in hospitalised patients, classified äs euthyroid, the free thyroxine values ranged frorn 11 to 28 pmol/1 and thyrotropin values from 0.5 to 5.9 mU/1.
Group 2: In the subgroup of selected patients, 5 patients died subsequently, and of these 3 patients had abnormal thyroid function tests at least one during follow üp (free thyroxine 11.3 pmöl/1, thyrotropin 0.22 mU/1; free thyroxine 9.7 pmol/1, thyrotropin 0.72 mU/1; free thyroxine 21.3 pmol/1, thyrotropin 4.4 mU/1). A further 3 patients had transiently abnormal results (tab. 4). Two patients had consistently high but fluctuating thyrotropin levels (12.6 to 6.6 mU/1 and 4.5 to 7.9 mU/1) over a period of 4 weeks, suggestive of subclinical hypothyroidism.
In the remaining 8 patients a shift of free thyroxine values to higher concentrations was observed äs the patient recovered. Free thyroxine and thyrotropin values feil within the reference ranges thoügh there was considerable intraindividual Variation during follow up ( fig.  5a,b) . In patients in the intensive care unit, classified äs euthyroid, free thyroxine ranged from 10-23 pmol/1 and thyrotropin from 0.22 to 5.9 mU/1.
Discussion
Several aspects of the thyrotropin and free thyroxine äs-says routinely in use in the laboratory were investigated during this evaluation. Precision, linearity and rnethod comparison for the Enzymun-Test® TSH and EnzymuriTest® FT 4 were acceptable for clinical use. The ftmctional assay sensitivity of 0.09 mU/1 suggested that this was a second generation assay. Both assays were practicable and easy to use.
Long term low dose heparin therapy used in an intensive cäre setting can cause increases in plasma free fatty acid concentrations. Additions oft pleic äcid, the rhost abun- dant non-esterified fatty acid present in the serum (17) , caused an increase in free thyroxine concentrations when levels reached approximately > 4 mmol/1. Free thyroxine by equilibrium dialysis responded similarly. However, the clinical relevance of this observation is yet to be determined äs the molar ratio of free fatty acids/ albumin that have a discernible effect on free thyroxine concentration is thought to vary from 2.5 (19, 20) to > 5.0 (16, 18) .
Because dependence on carrier proteins might reduce the clinical usefulness of free thyroxine methods (21), we assessed the effect of albumin on the Enzyme-Test® FT 4 assay.
Our results suggest that the current assay, like the equi^· librium dialysis method is relatively free of albumin or thyroxine binding globulin dependence. This agrees with the manufacturer's claim that the horseradish peroxidase label is prevented from occupying serum triyroxine binding sites by steric hindrance.
Free thyroxine concentrations rrieasured by the Enzymun-Test® assay decreases during the course of pregnancy, although individual results are only slightly below the reference ränge. As the technique yields results within the reference ränge in subjects with increases in thyroxine binding globulin äs in hormone replacement or oestrogen therapy, at least part of the decrease can be assumed to be physiological (22) ; such individuals remain euthyroid with thyrotropin levels within the reference ränge.
The study suggests that there is no perfect free thyroxine assay, äs the theoretical premise of non-interference by antibodies in the assay is not fulfilled. This has been previously reported for other non-analogue assays (23, 24) . The nature of the antibody, however, is yet to be determined. Anti-sheep antibodies affecting a radioimmunoassay for thyrotropin has been reported (25) . These heterophilic antibodies can prevent the binding of the biotin labelled thyroxine antibodies to the streptavidin coated tubes, leading to spuriously high values. An isolated increase in free thyroxine should therefore be viewed with caution.
Non-thyroidal illness has been shown to affect thyroid function tests (26) (27) (28) (29) (30) (31) (32) . Thyroid function tests are therefore optimally performed in ambulatory and otherwise well patients, but there is a clinical need for determining the presence or absence of thyroid disease in patients with non-thyroidal illness. This is especially true in elderly patients > 50 years, who suffer from chronic illnesses and benefit from treatment for thyroid dysftmction äs well äs in patients with myocardial infarction where the presence or absence of thyroid disease is to be established. The study shows that in such patients, normal, low or borderline high thyrotropin/free thyroxine values are possible. In most patients abnormalities in thyroid function tests were, however, transient. Furthermore, we noted that nqne of the patients had a subnormal thyrotropin and increased free thyroxine (suggestive of hyperthyroidism) or a high concentration of thyrotropin with a low free thyroxine (suggestive of hypothyroidism). Abnormal thyroid function tests associated with nori-thyroidal illness, therefore caused few interpretative problems. Persistent increased or decreased thyrotropin concentrations during follow up may indicate subclinical hyper/hypothyroidism.
The average age in both groups of patients with nonthyroidal illness was 74 years. Although it has been reported that aging influences the outcome from thyroid function testing (12) , there is evidence that 'normal' aging has little effect, i. e. when pharmacological and methodological effects are removed (34) . The low prevalence of subnormal thyrotropin concentrations and the transient nature of the abnormalities, confirmed in previous studies with younger patients (27) , suggest that the changes observed during non-thyroidal iilness are not an age-felated effect.
Doctor et al. (35) showed that in a large proportion of patients with non-thyroidal illness other non-analogue free thyroxine assays showed values above the reference ränge. Coupled with the observation of anomalous thyrotropin values in non-thyroidal illness, a strategy recommended in a hospital setting is the use of thyrotropin and free thyroxine assays on all patients with noii-thyroidal illness (36, 37) . The present study suggests that with the Enzymun-Test® technology diagnostic problems will arise infrequently with this approach. Further, automation of free thyroxine and thyrotropin will facilitate their concurrent measurement with minimal increase in manpower and laboratory time.
In summary, we found the Enzymun-Test® assays to be precise, of adequate sensitivity and robust, However, in a hospital setting, non-thyroidal illness and in vitro assay interference may compromise the clinical sensitivity and specificity of thyrotropin and free thyroxine measurement, such that measurement r of both analytes is required for initial evaluation of thyroid function. Automated immunoassay analysers, such äs the ES300, make this approach econoinically more feasible.
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